CSK may be a potential prognostic biomarker reflecting the immune status of gastric cancer

Eur Rev Med Pharmacol Sci. 2024 Jan;28(1):221-230. doi: 10.26355/eurrev_202401_34907.

Abstract

Objective: C-terminal Src kinase (CSK), a sarcoma (Src) homologous family kinase, is one of the most important negative regulators. It acts as a tumor suppressor by inhibiting the activity of Src family tyrosine kinases. Paradoxically, CSK is highly expressed in a variety of common tumors. Therefore, we report the expression profile of CSK in pan-cancer patients, focusing on the prognostic value, immune infiltration pattern, and biological function of CSK in gastric cancer.

Materials and methods: We used the TCGA database to analyze CSK expression, clinical relevance, prognostic significance, assessment of the tumor immune microenvironment, and GO and Kegg enrichment analysis based on co-expressed genes using a bioinformatics approach.

Results: CSK is a protective factor in gastric cancer, and its expression correlates with the level of immune cell infiltration and immune checkpoint molecules.

Conclusions: Our findings suggest that CSK is an independent prognostic factor in gastric cancer and may predict molecular targeting and immunotherapy and provide ideas for its therapeutic strategy.

MeSH terms

  • Biomarkers / metabolism
  • CSK Tyrosine-Protein Kinase / metabolism
  • Humans
  • Phosphorylation
  • Prognosis
  • Stomach Neoplasms* / diagnosis
  • Stomach Neoplasms* / genetics
  • Tumor Microenvironment
  • src-Family Kinases* / metabolism

Substances

  • src-Family Kinases
  • CSK Tyrosine-Protein Kinase
  • Biomarkers